Enanta Pharma (NASDAQ: ENTA) reported Q4 EPS of ($1.33), $0.79 better than the analyst estimate of ($2.12). Revenue for the quarter came in at $18.9 million versus the consensus estimate of $20.56 million.

Financial Guidance for Fiscal Year 2024

Research and Development Expense: $100 million to $120 million (reduced from $163.5 million of actual expense in 2023)
General and Administrative Expense: $45 million to $50 million (reduced from $52 million of actual expense in 2023; guidance includes an increase in legal fees associated with the company’s patent infringement lawsuit)

For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.